fda drug safety communication naion semaglutide 2025 Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

25.84

★★★★☆4.8 (126)

FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize

26.07

★★★★★4.9 (98)

Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies

20.70

★★★★★5.0 (157)

FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in the U.S. drug supply chain. The agency recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg that were

29.91

★★★★★4.7 (84)

Is Semaglutide Linked to NAION? A Case Report on a Rare Ocular Complication

24.25

★★★★★4.9 (203)

📣As of March 19, 2025, tirzepatide may 🚫NO LONGER 🚫 legally be made/distributed/sold by compounding pharmacies. On May 22, 2025 the same will be true of semaglutide. BRAND NAME ONLY is legal (Ozempic,

26.79

★★★★★5.0 (176)

2025 Novel Small Molecule FDA Drug Approvals

27.43

★★★★★4.8 (132)